In 2025, the latest biosimilar policy developments included bipartisan efforts to enhance affordability and reduce barriers ...
The US Food and Drug Administration will take steps to streamline the development of generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to accelerate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback